Details for Patent: 8,476,268

Which drugs does patent 8,476,268 protect, and when does it expire?

Patent 8,476,268 protects VIJOICE and PIQRAY and is included in three NDAs.

This patent has sixty patent family members in fifty countries.

Summary for Patent: 8,476,268

Title:	Pyrrolidine-1,2-dicarboxamide derivatives
Abstract:	The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
Inventor(s):	Robin Alec Fairhurst, Vito Guagnano, Patricia Imbach-Weese, Giorgio Caravatti, Pascal Furet
Assignee:	Novartis AG
Application Number:	US13/488,589
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,476,268

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	VIJOICE	alpelisib	GRANULE;ORAL	218466-001	Apr 24, 2024		RX	Yes	Yes	8,476,268		Y	Y
Novartis	PIQRAY	alpelisib	TABLET;ORAL	212526-001	May 24, 2019		RX	Yes	No	8,476,268		Y	Y
Novartis	PIQRAY	alpelisib	TABLET;ORAL	212526-002	May 24, 2019		RX	Yes	No	8,476,268		Y	Y
Novartis	PIQRAY	alpelisib	TABLET;ORAL	212526-003	May 24, 2019		RX	Yes	Yes	8,476,268		Y	Y

Foreign Priority and PCT Information for Patent: 8,476,268

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08164104	Sep 10, 2008

International Family Members for US Patent 8,476,268

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2331537		C02331537/01	Switzerland
European Patent Office	2331537		301071	Netherlands
European Patent Office	2331537		LUC00186	Luxembourg
European Patent Office	2331537		CA 2020 00054	Denmark